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A brief overview is provided of some of the general safety and risk assessment procedures
used by the different centers of the U.S. Food and Drug Administration (U.S. FDA) to evaluate
low-level exposures. The U.S. FDA protects public health by regulating a wide variety of
consumer products including foods, human and animal drugs, biologics, and medical devices
under the federal Food, Drug, and Cosmetic Act. The diverse legal and regulatory standards in
the act allow for the consideration of benefits for some products (e.g., drugs) but preclude them
from others (e.g., food additives). When not precluded by statutory mandates (e.g., Delaney
prohibition), the U.S. FDA considers both physiologic adaptive responses and beneficial effects.
For the basic safety assessment paradigm as presently used, for example in the premarket
approval of food additives, the emphasis is on the identification of adverse effects and no
observed adverse effect level(s) (NOAEL). Generally, the NOAEL is divided by safety factors to
establish an acceptable exposure level. This safety assessment paradigm does not preclude
the consideration of effects whether they are biologically adaptive or beneficial at lower dose
levels. The flexibility to consider issues such as mechanisms of action and adaptive and beneficial
responses depends on the product under consideration. For carcinogenic contaminants and
radiation from medical devices, the U.S. FDA considers the potential cancer risk at low exposure
levels. This generally involves downward extrapolation from the observed dose-response range.
The consideration of adverse effects of other toxicologic end points (e.g., reproductive,
immunologic, neurologic, developmental) associated with low exposure levels is also becoming
more of a reality (e.g., endocrine disrupters). The evaluation of the biologic effects of low-level
exposures to toxic substances must include whether the effect is adverse or a normal
physiologic adaptive response and also determine the resiliency of a physiologic system. The
public health mandate of the U.S. FDA includes an active research program at the National
Center for Toxicological Research and the other U.S. FDA centers to support the regulatory
mission of the U.S. FDA. This includes the development of knowledge bases, predictive
strategies, and toxicologic studies to investigate effects at the lower end of the dose-response
range. Because of the wide diversity of legal and regulatory standards for various products
regulated by the U.S. FDA, agency-wide safety and risk assessment procedures and policies
generally do not exist. - Environ Health Perspect 106(Suppl 1):391-394 (1998).
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Introduction
Three questions posed regarding how regu-
latory/public health agencies consider the
biologic effects oflow-level exposures are as
follows. Short answers to these questions are
given here; more detailed discussion follows.
First, does the understanding of the
mechanisms oftoxicity affect how the agency
assesses risks from exposures to toxic sub-
stances? Yes, unless specifically precluded
from doing so by statute, e.g., the Delaney
clause (1) ofthe Food, Drug, and Cosmetic
Act (FDCA). In most cases there are no
available data to consider.
Second, does an understanding of the
mechanisms by which the body adapts
(e.g., detoxifies, repairs, etc.) to the effects
of exposures to toxic substances affect how
the U.S. Food and Drug Administration
(U.S. FDA) assesses risks from exposures to
toxic substances? Yes, unless specifically
precluded from doing so by statute, e.g.,
the Delaney clause (1).
Third, if low doses of toxic agents
induce apparently beneficial responses
(e.g., enhanced longevity, lower incidence
ofdisease), how does and/or could the U.S.
FDA address this? The U.S. FDA is
required by law to consider the efficacy of
human and animal drugs, biologics, and
medical devices. Benefits, except where
specifically excluded by statute (e.g., food
additives) are considered. It is generally
difficult to weigh risks versus benefits.
A briefoverview is provided of some of
the general safety and risk assessment pro-
cedures used by each ofthe U.S. FDA cen-
ters to evaluate low-level exposures oftoxic
agents in consumer products. Different
centers ofthe U.S. FDA are responsible for
the safety of foods and cosmetics, veteri-
nary drugs, medical devices and radiation,
human drugs, and biologics.
Center for Food Safety
and Applied Nutrition
The Center for Food Safety and Applied
Nutrition (CFSAN) is responsible for
ensuring the safety of cosmetics and the
food supply in two major areas: food addi-
tives and natural and anthropogenic envi-
ronmental contaminants. The legal and
regulatory standards in the federal FDCA
(2) that apply to these areas allow for the
consideration ofbenefits for environmental
contaminants, but may preclude them
from consideration for food additives (e.g.,
prohibition by the Delaney clause) (1).
Even for foodborne contaminants, benefits
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may or may not be taken into account if
the hazard or risk assessment is confined to
the delineation ofa safe level ofexposure.
This depends on which portion ofthe act
serves as the basis for a regulatory action
(e.g., Section 402 of the FDCA: may or
ordinarily render injurious to health stan-
dard). For carcinogenic contaminants in
foods, food and color additives, and cos-
metics, the CFSAN considers the potential
cancer risk at low exposure levels. This
involves the downward linear extrapolation
from the observed dose-response range
(3-5), which is primarily observed in a
chronic animal bioassay. When not pre-
cluded by statutory mandates, the CFSAN
considers other relevant issues such as
mechanism oftoxicity, biologic or physio-
logic adaptive responses, and beneficial
responses at low exposure levels. The basic
safety assessment paradigm as presently
used-for example in the premarket
approval of food additives-does not
include consideration ofthese issues. The
basic safety assessment paradigm generally
involves dividing no observed adverse
effect level(s) (NOAEL) bysafety factors to
derive an acceptable exposure level to toxic
agents. Indeed, the act that concerns food
additives mandates the use ofsafety factors
with appropriate experimental animal data
(e.g., a NOAEL). At the same time there
are no specific legal or regulatory barriers
that would prohibit the consideration of
such information. Furthermore, the safety
assessment paradigm does not preclude the
consideration ofthe mechanism oftoxicity
and physiologically adaptive or beneficial
effects at low-dose levels. With the current
safety assessment paradigm the emphasis is
on the identification ofadverse effects, the
NOAEL, and use ofsafety (uncertainty)
factors based primarily on laboratory ani-
mal studies. Presently the safety and risk
paradigm does not accommodate low-dose
beneficial effects information. Mechanistic
information, when available, can be used
qualitatively in identifying the appropriate
study for selecting the NOAEL. If an
acceptable daily intake is derived that falls
within the dose range and demonstrates a
beneficial or physiologic effect, there is
presently no general process in place that
allows us to resolve this conflict. Current
processes to consider such conflicting
information are ad hoc. Invariably, the
estimated safe level ofexposure drives the
decision-making process, and the issues of
low-dose beneficial or physiologic effects
have little impact. The flexibility to con-
sider these issues depends on the product
under consideration. For example, unlike
direct food additives, with foodborne cont-
aminants these issues can be given more
consideration and are more likely to have a
greater impact on decision making. Con-
sideration ofbenefits depends on the mar-
gin ofsafety for a contaminant, i.e., the
ratio of the acceptable level to the human
exposure level. If the differential between
the estimated exposure and acceptable or
tolerable daily intake for contaminants is
great enough, benefits will generally be
considered. Ifthe differential is small, con-
sideration ofbenefits is more problematic
and similar to the difficulty described above
for food additives. The consideration of
adverse effects of some toxicologic end
points (e.g., reproductive, immunologic,
neurologic, developmental) associated with
low exposure levels is also becoming more
and more ofa reality (e.g., endocrine dis-
rupters). As our ability to measure biologic
events at lower exposure levels becomes
more sensitive, our commensurate ability to
interpret their clinical and health signifi-
cance must keep pace. The consideration of
biologic and physiologic effects oflow-level
exposures to toxic substances must begin
with the determination as to whether the
effect is deemed to be adverse or a normal
physiologic adaptive response. There is a
need to consider the resiliency or reservoir
ofresponse ofa physiologic system. Ifexpo-
sure to a toxic substance is deemed not to
be adverse but it adds to a cumulative insult
that diminishes reserve physiologic capac-
ity, then the issue ofwhether a physiologic
effect is adverse must be defined in this
context ofdiminished physiologic capacity.
CenterforVeterinary
Medicine
The Center forVeterinary Medicine (CVM)
evaluates laboratory and clinical data for
animal drugs and feed additives for food
and nonfood animals. Management ofthe
risk ofthese products (derived from regula-
tory risk-assessment decisions for the use of
animal drugs and feed additives) include
the development ofsafe concentration val-
ues in food, residue tolerances for postmar-
keting monitoring, and withdrawal periods
forslaughter following drug treatment.
The diethylstilbestrol proviso (6,7) of
the Delaney clause (1) permits the use ofa
carcinogenic drug or feed additive for ani-
mals under certain conditions. The proviso
stipulates that a suspect or known carcino-
gen can be administered to animals ifno
residue ofthe drug or additive is found in
edible products for human consumption
by methods prescribed by the U.S. FDA
Commissioner. The U.S. FDA, by regula-
tion, has provided that the permitted con-
centration of a potentially carcinogenic
residue corresponds to that concentration
that would give a maximum lifetime risk of
cancer of 1 in 1 million (the operational
definition of no residue). An analytical
method sensitive enough to detect chemical
residues at this level is then required to pro-
vide adequate assurance ofsafety. This low
level must be determined from the results
ofchronic studies ofthe veterinary drug.
These studies are generally conducted in
rodents for 2 years, with the highest dose at
or near the maximum tolerated dose to
elicit potential carcinogenic and/or chronic
health effects. Hence, risks associated with
low-level exposures require an extrapolation
procedure described previously for food-
borne contaminants. A nonthreshold, con-
servative, linear-at-low-dose extrapolation
procedure for tumor incidence is used to
provide estimates ofan upper limit oflow-
dose cancer risk (3-5). The justification for
this procedure is that it provides an upper
bound for dose responses that curve upward
in the low-dose region (3,4). For a geno-
toxic carcinogen that reacts directly with
DNA, presumably a single molecule at the
right place and time can initiate a carcino-
genic process in a cell but few initiated cells
progress to cancer. Further, for those ongo-
ing carcinogenic processes that produce
tumors in unexposed control animals, a
threshold dose for that process, ifany, has
already been surpassed by endogenous or
exogenous factors other than the agent in
question. In such a case any small amount
ofa chemical that augments this ongoing
process will result in a small increase in
cancer incidence that is approximately lin-
ear at low levels ofexposure (8). Thus, in
the absence ofother information, linear
extrapolation over the low-dose range is
considered prudent (3-5,8). Adoption of
the concentration ofan animal drug residue
in food associated with a conservative esti-
mate ofcancer risk ofless than 1 per mil-
lion for lifetime consumption is considered
to satisfy the U.S. FDA's responsibility to
ensure with reasonable certainty that the
publicwill not be harmed.
Further, chemicals that appear
carcinogenic at high doses but not at low
doses are currently under review at the
CVM. Hence, low-dose linearextrapolation
may not be appropriate. For example, at
high doses an animal drug may disrupt the
homeostatic control and lead to a chronic
elevation in the thyroid-stimulating
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hormone. This elevation in turn leads to
increased thyroid growth and thyroid
tumors. Homeostatic control appears to
minimize hormonal imbalance at low doses
with no additional risk ofthyroid tumors.
Thus, there appears to be a dose below
which thyroid tumors would not be pro-
duced or, at most, there might be a negligi-
ble increase in tumor incidence. Hence,
mechanisms oftoxicity that cause adverse
effects only under specific conditions of
exposure, e.g., high doses, are currently
under consideration by the CVM.
Centerfor Devices
and Radiological Health
The Center for Devices and Radiological
Health (CDRH) administers the medical
device and electronic product radiation
control provisions ofthe federal FDCA. By
implementing these provisions the CDRH
evaluates risks in the context ofapremarket
review system that includes balancing risks
and benefits.
One issue that arises in the premarket
review ofdevices is material safety. Some
medical devices contain chemicals that can
leach out into surrounding tissue in poten-
tially toxic amounts. The doses ofsuch
leachants are generally small and amenable
to risk assessment by classical procedures.
For carcinogenic leachants low-dose linear
extrapolation techniques can be used for
chemical contaminant risk assessment
(3-5). Often one ofthe most challenging
problems is the determination of the low
levels ofexposures to leachants.
The CDRH has used risk-assessment
methodologies to estimate the risks associ-
ated with radiation-emitting products. For
example, assessments have been made for
malfunctioning diagnostic and therapeutic
X-ray machines to determine ifthere were
any significant risks ofgenetic, carcino-
genic, or reproductive health effects. Skin
cancer risks have been estimated by the
CDRH for ultraviolet-emitting sunlamps,
tungsten halogen lamps, and fluorescent
lamps. Risk assessments have also been
conducted for the potential adverse health
effects produced by exposure to microwave
and extremely-low-frequency radiation
from products such as cellular telephones
and police radar systems and for possible
adverse health effects of ultrasound diag-
nostic imaging systems. Based on the
mechanisms and experimental data for ion-
izing radiation, a linear dose response has
been used for estimating the risk of
leukemia and a linear-quadratic model for
solid tumors. For genetic effects from
ionizing radiation, exposure limits have
been set on the assumption that a small
addition to background radiation exposure
would be tolerable. For example, the televi-
sion receiver standard has been set as 5% of
natural background radiation exposure to
the gonads.
The development of adverse health
effects after exposure to microbially conta-
minated products represents a potentially
significant public health concern. The
CDRH is collaborating with the National
Center for Toxicological Research (NCTR)
to develop an approach for characterizing
the risk posed by exposure to microbially
contaminated medical devices. Specifically,
this approach is being developed to provide
additional scientific bases for sterility assur-
ance level(s) (SAL) established by the
CDRH fordevices. An SAL is the probabil-
ity ofat least one microorganism, poten-
tially capable ofmultiplying and producing
infections, existing on a device after it has
been submitted to a sterilization process.
Centerfor Drug Evaluation
and Research
The mission of the Center for Drug
Evaluation and Research (CDER) is to
approve drugs for marketing that are safe,
effective, and provide benefits that out-
weigh their risks. Additionally, the CDER
helps ensure that product quality and
safety are maintained during marketing.
Risk assessment in the drug approval
process is unique because assessments ofthe
risks ofadrug are conducted based on actual
studies ofthe drug in humans at levels of
exposure likely to be encountered by the
population using the drug after approval.
The level of exposure in clinical trials is
determined on the basis ofdose-response
and dose-ranging studies designed to esti-
mate the effective dose and conducted in
both animals and humans. The risks identi-
fied during the controlled clinical trials are
evaluated for the general population who
will be using the drug. If the benefits of
drug therapy exceed the risks, the drug will
be approved.
Predinical animal studies are conducted
to identify the potential hazards associated
with a drug. Theyprovide early approxima-
tions ofthe margin ofsafety (ratio oftoxic
dose in animals to the intended human
dose) ofthe drug as well as estimates ofeffi-
cacy. The primary purpose of animal
studies is to identify highly toxic drugs and
drugs that are potentially carcinogenic,
genotoxic, or reproductive/developmental
toxicants. These results are used in the
design offuture clinical studies to minimize
risks ofparticipants. Concern about toxicity
depends on the mode ofaction, efficacy,
and duration ofdrug use. Traditional low-
dose extrapolation is rarely used to evaluate
the results ofpreclinical animal studies for
drugs. It may be used, for example, to
estimate the risk associated with contami-
nants in drug products in a manner similar
to the low-dose methods described earlier.
More commonly, a risk assessment for a
drug involves mechanistic data and a
weight-of-evidence approach for a qualita-
tive risk/benefit analysis. This approach
uses information from preclinical studies
and relevant clinical studies to try to deter-
mine relevance ofthe findings for human
risk under the proposed conditions ofuse.
The conclusion from such an analysis is
then qualitatively factored in with the
drug's known clinical characteristics in the
approval decision.
Centerfor Biologics
Evaluation and Research
The Center for Biologics Evaluation and
Research (CBER) is responsible for protect-
ing and enhancing the public health by
ensuring the purity, potency, safety, effi-
cacy, and availability ofbiologic products.
Biologic products indudevaccines, antisera,
allergenic extracts, blood, blood products,
and blood derivatives.
Biologic products for the most part are
complex materials, often derived from liv-
ing materials from living donors capable of
transmitting infectious agents. Thus, they
must be closely evaluated and monitored
during the production process and in
postapproval surveillance to ensure the
continued safety and efficacy ofthe prod-
uct. Evaluations involve review ofsource
and quality ofthe starting material, purifi-
cation, reagents, and contaminants, and
include validation of removal or test of
residual levels in the final product.
Safety concerns relating to biologic
products have resulted in the design of
studies to assess carcinogenic (including
tumorigenic) and noncarcinogenic end
points (e.g., infection, aberrant immune
responses, immunosuppression, etc.). The
diversity ofboth traditional and novel bio-
logic products has often demanded the use
ofnontraditional preclinical methods and
approaches to assess potential risks. Adven-
titious agents such as retroviruses and other
persistent viral infections may be associated
with acute disease with varying incubation
periods, which may be followed by a
period ofclinical latency prior to the onset
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ofclinically evident malignancies or other
chronic disease. The guidance on viral vali-
dation is intended to diminish the risk of
transmission of infectious agents to the
recipient and to the general public.
The techniques used for estimating
risks associated with contaminants, excipi-
ents, and leachants from devices used to
deliver biologic products are similar to the
low-dose safety assessment procedures
discussed previously.
The CBER approach to risk assessment
and risk management decision-making
processes for biologic product approval and
surveillance is similar to that ofthe CDER.
The availability ofcontrolled human data
during the premarketing phase reduces the
uncertainty ofexposure and thus provides
important data not only to assess the
predictive value ofpreclinical animal data
but to select the most appropriate animal
model(s) to improve the extrapolation of
such data.
National Centerfor
Toxicological Research
The NCTR conducts scientific research
that supports and anticipates the current
and future regulatory needs of the U.S.
FDA. This involves fundamental and
applied research designed specifically to
define biologic mechanisms of action
underlying the toxicity ofproducts regu-
lated by the U.S. FDA. This research is
aimed at understanding critical biologic
events in the expression of toxicity and at
developing methods to improve assessment
ofhuman exposure, susceptibility, and risk.
Toxicologic research has traditionally
sought to understand basic tenets ofbio-
logic and biochemical sciences. As toxicol-
ogy is evolving from a descriptive science
to one based on mechanistic understand-
ing, the hope often is expressed that mech-
anistic information will eventually reduce,
and in some cases eliminate, uncertainty in
predicting the toxicity ofchemical products.
Research on mechanisms ofaction is gener-
ally expensive and complex. Mechanistic
data on occasion can be used to discount a
mode ofaction, but are seldom adequate to
validate a mode ofaction.
One aspect ofthe NCTRprogram is to
conduct concept-driven research that
addresses longer-range regulatory needs of
the U.S. FDA. For example, studies are
being conducted using advanced molecu-
lar biology on carcinogenic agents that
exert their effects through indirect or sec-
ondary mechanisms, dietary modulation
oftoxicity, and foreign body (biomaterial)
carcinogenesis research to assess immune
response and identify the role ofoxidative
DNA damage. Measurements of DNA
adducts, cellular proliferation, and apopto-
sis are being considered for improvement
of predicting cancer risk. Biologically
based pharmacokinetic models are being
developed to estimate doses oftoxicants to
fetuses during pregnancy. Knowledge of
receptor mediation or saturable toxifica-
tion and detoxification influences the
choice ofdose-response models for pre-
dicting toxicity. Gradually our knowledge
ofmechanisms oftoxicity also is improv-
ing our ability to estimate benchmark
doses (9) associated with low incidence of
adverse events.
In addition to research conducted by the
NCTR, a pool ofscientists assists other U.S.
FDAcenters on specific scientific issues.
Summary
Under the federal FDCA the U.S. FDA
regulates a diverse array ofconsumer prod-
ucts including food, drugs, cosmetics, ani-
mal drugs, biologics, and medical devices.
The legal and regulatory standards permit
the consideration of benefits for some
products. Both adaptive biologic and bene-
ficial health effects are considered when
not precluded by statutes. For end points
other than cancer, the emphasis is on the
identification of the NOAEL and the use
ofsafety factors to establish acceptable lev-
els ofexposure. The consideration of the
biologic effects oflow-level exposures to
toxic substances must determine whether
an effect is adverse or a normal adaptive
response. For carcinogenic contaminants
cancer risk at low exposure levels is gener-
ally estimated bylinear extrapolation below
the experimental dose range.
The U.S. FDA is conducting research
on toxicologic effects to develop knowl-
edge bases and predictive strategies for
biologic effects at the low end of the dose
range corresponding to human exposure
levels. Because of the wide diversity of
legal and regulatory standards for various
consumer products regulated by the U.S.
FDA, agency-wide safety and risk assess-
ment procedures and policies generally do
not exist.
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